This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

That’s especially true for Phase I clinical ... its path into early-stage drug development, bolstering America’s competitive edge without compromising patient safety. In the U.S., one of ...

In the pivotal, Phase III NUC-5 trial, (NCT03872921), NCA showed statistical superiority over placebo in achieving the ...

Therini Bio reveals promising Phase 1a trial results for THN391, a potential breakthrough treatment for neurodegenerative ...

While Quantum computing has been reported to be five years away for many years now, companies are preparing for it by setting ...

New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies ... and antibody-drug conjugates (ADCs) ...